Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.95)
# 1,549
Out of 4,413 analysts
56
Total ratings
35.38%
Success rate
-8.07%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Maintains: Buy | $36 → $26 | $6.11 | +325.53% | 2 | Apr 30, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $21 → $17 | $13.28 | +28.01% | 3 | Apr 26, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $100 → $107 | $72.73 | +47.12% | 3 | Apr 23, 2024 | |
| CRVO CervoMed | Maintains: Buy | $50 → $65 | $24.17 | +168.93% | 2 | Apr 8, 2024 | |
| STOK Stoke Therapeutics | Maintains: Buy | $18 → $21 | $11.56 | +81.66% | 2 | Mar 26, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $18 → $7 | $2.54 | +175.59% | 3 | Mar 14, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $40 → $33 | $17.05 | +93.55% | 6 | Mar 12, 2024 | |
| CARA Cara Therapeutics | Maintains: Buy | $11 → $10 | $0.76 | +1,218.22% | 3 | Mar 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $310 → $305 | $216.13 | +41.12% | 10 | Feb 20, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $150 | $143.03 | +4.87% | 6 | Dec 7, 2023 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $4.60 | +334.78% | 2 | Sep 1, 2023 | |
| CYBN Cybin | Reiterates: Buy | $5 | $0.35 | +1,328.57% | 3 | Sep 1, 2023 | |
| CMPS COMPASS Pathways | Maintains: Buy | $60 → $50 | $8.48 | +489.62% | 1 | Aug 22, 2023 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $10 → $14 | $8.36 | +67.46% | 2 | May 10, 2023 | |
| CLNN Clene | Maintains: Buy | $10 → $6 | $0.44 | +1,273.00% | 2 | Oct 4, 2022 | |
| GHRS GH Research | Maintains: Buy | $45 → $41 | $11.95 | +243.10% | 2 | Apr 13, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | n/a | $40.18 | - | 3 | Aug 3, 2021 | |
| TEVA Teva Pharmaceutical | Upgrades: Buy | n/a | $13.98 | - | 1 | Jan 31, 2017 |
Annovis Bio
Apr 30, 2024
Maintains: Buy
Price Target: $36 → $26
Current: $6.11
Upside: +325.53%
Sage Therapeutics
Apr 26, 2024
Maintains: Hold
Price Target: $21 → $17
Current: $13.28
Upside: +28.01%
Intra-Cellular Therapies
Apr 23, 2024
Maintains: Buy
Price Target: $100 → $107
Current: $72.73
Upside: +47.12%
CervoMed
Apr 8, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $24.17
Upside: +168.93%
Stoke Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $18 → $21
Current: $11.56
Upside: +81.66%
BioXcel Therapeutics
Mar 14, 2024
Maintains: Buy
Price Target: $18 → $7
Current: $2.54
Upside: +175.59%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $17.05
Upside: +93.55%
Cara Therapeutics
Mar 6, 2024
Maintains: Buy
Price Target: $11 → $10
Current: $0.76
Upside: +1,218.22%
Biogen
Feb 20, 2024
Maintains: Buy
Price Target: $310 → $305
Current: $216.13
Upside: +41.12%
Neurocrine Biosciences
Dec 7, 2023
Reiterates: Buy
Price Target: $150
Current: $143.03
Upside: +4.87%
Zevra Therapeutics
Sep 1, 2023
Reiterates: Buy
Price Target: $20
Current: $4.60
Upside: +334.78%
Cybin
Sep 1, 2023
Reiterates: Buy
Price Target: $5
Current: $0.35
Upside: +1,328.57%
COMPASS Pathways
Aug 22, 2023
Maintains: Buy
Price Target: $60 → $50
Current: $8.48
Upside: +489.62%
Voyager Therapeutics
May 10, 2023
Maintains: Buy
Price Target: $10 → $14
Current: $8.36
Upside: +67.46%
Clene
Oct 4, 2022
Maintains: Buy
Price Target: $10 → $6
Current: $0.44
Upside: +1,273.00%
GH Research
Apr 13, 2022
Maintains: Buy
Price Target: $45 → $41
Current: $11.95
Upside: +243.10%
Biohaven Pharmaceutical Holding Company
Aug 3, 2021
Maintains: Buy
Price Target: n/a
Current: $40.18
Upside: -
Teva Pharmaceutical
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $13.98
Upside: -